Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline

Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

What in the world has happened since COP27? – Pharmaceutical Technology

After COP27 the European Union introduced a new plan. Credit: Alexandros Michailidis via Shutterstock. The world is currently at an environmental crisis point with climate

November 8, 2023

FDA delays action on Lilly’s donanemab, intent on advisory committee meeting – Pharmaceutical Technology

Share this article Lilly is looking to join Eisai’s Lequembi on the market for the treatment of Alzheimer’s. Credits: SewCreamStudio/Shutterstock.com As Eli Lilly’s donanemab inches

March 8, 2024

The Globe and Mail Explores Psychedelics Breakthrough in Health

The TDR Three Key Takeaways for Psychedelics in the Globe and Mail: The Globe and Mail’s articles on psychedelics underline a significant shift towards their

April 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.